Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;48(8):300060520948750.
doi: 10.1177/0300060520948750.

Altered levels of circulating natural antibodies against VEGFR1-derived peptide in atherosclerosis

Peng Wang  1 , Siqi Liu  1 , Zhenqi Wang  2 , Huan Zhao  1 , Xuan Zhang  1
Affiliations

Altered levels of circulating natural antibodies against VEGFR1-derived peptide in atherosclerosis

Peng Wang et al. J Int Med Res. 2020 Aug.

Abstract

Background: Several lines of evidence have pointed to a protective role of natural antibodies in chronic diseases like atherosclerosis and cancer. Vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2 are important regulators of angiogenesis and may be involved in the development of atherosclerosis. In this retrospective study, we developed an in-house enzyme-linked immunosorbent assay to assess whether natural IgG levels against VEGFR1 and the regulatory T cell markers CD25 and FOXP3 were associated with atherosclerosis.

Methods: A total of 218 patients with atherosclerosis and 200 healthy controls were enrolled. All patients had atherosclerotic carotid plaques. Carotid intima-media thickness was analyzed using a diagnostic ultrasound system.

Results: Plasma anti-VEGFR1 IgG levels were significantly lower in patients with atherosclerosis than control subjects. Decreased anti-VEGFR1 IgG levels were more obvious in male patients. Spearman correlation analysis showed no significant correlation between natural IgG levels and carotid intima-media thickness.

Conclusions: Decreased levels of anti-VEGFR1 IgG may be involved in development of atherosclerosis and related conditions.

Keywords: Atherosclerosis; angiogenesis; enzyme-linked immunosorbent assay; natural antibody; peptide; vascular endothelial growth factor receptor 1.

PubMed Disclaimer

References

    1. Ou HX, Guo BB, Liu Q, et al. Regulatory T cells as a new therapeutic target for atherosclerosis. Acta Pharmacol Sin 2018; 39: 1249–1258. - PMC - PubMed
    1. Taleb S. Inflammation in atherosclerosis. Arch Cardiovasc Dis 2016; 109: 708–715. - PubMed
    1. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204–212. - PubMed
    1. Butcher MJ, Filipowicz AR, Waseem TC, et al. Atherosclerosis-driven Treg plasticity results in formation of a dysfunctional subset of plastic IFNgamma+ Th1/Tregs. Circ Res 2016; 119: 1190–1203. - PMC - PubMed
    1. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508–519. - PubMed

Substances